Background: Threatened abortion is a common complication of pregnancy. In order to prevent miscarriage progesterone in various forms is administered in patients. This is done to allow pregnancy to proceed further beyond twenty week of gestation. Aim: To compare gravibinan (injected) with utrogestan/cyclogest (intra vaginal administration) in reduction of miscarriages. Study design: Case control study Place and duration of study: Department of Obstetrics & Gynecologiy, Mohtrama Benzair Bhutto Shaheed Medical College Mirpur and Department of Pediatric, Shaikh Zayed Hospital Lahore from 1st April 2020 to 30th September 2020. Methodology: Pregnant women, who had vaginal bleeding until 20 weeks of their pregnancy, were assessed for inclusion. Participants were divided into three groups. Group A was given gravibinan, Group B was given utrogestan and Group C was given cyclogest. Results: Women infested with gravibinan had 20% those who still had miscarriage while the number of miscarriages significantly decreased to 14.2% in utrogestan group and 13.63% in cyclogest group (p<0.005). Conclusion: Cyclogest proved a better drug of choice for reducing miscarriages. Keywords: Miscarriages, progesterone, pregnancy
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.